{"id":"NCT04809220","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes","officialTitle":"A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Two Doses of Dulaglutide in Combination With a Single Oral Antihyperglycemic Medication or as Monotherapy in Japanese Patients With Type 2 Diabetes Mellitus (AWARD-JPN: Assessment of Weekly Administration of LY2189265 in Diabetes - JAPAN)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-04-13","primaryCompletion":"2022-10-01","completion":"2023-04-26","firstPosted":"2021-03-22","resultsPosted":"2023-09-21","lastUpdate":"2024-05-22"},"enrollment":591,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus","Diabetes Mellitus, Type 2","Glucose Metabolism Disorders","Metabolic Disease","Endocrine System Diseases","Hypoglycemic Agents","Type 2 Diabetes Mellitus (T2DM)"],"interventions":[{"type":"DRUG","name":"Dulaglutide","otherNames":["LY2189265"]},{"type":"DRUG","name":"Oral antihyperglycemics","otherNames":[]}],"arms":[{"label":"Dulaglutide 1.5 milligram (mg)","type":"EXPERIMENTAL"},{"label":"Dulaglutide 0.75 mg","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of 2 doses of dulaglutide in Japanese participants with type 2 diabetes. The study duration is approximately 58 weeks.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26","timeFrame":"Baseline, Week 26","effectByArm":[{"arm":"Dulaglutide 1.5 mg","deltaMin":-1.53,"sd":0.043},{"arm":"Dulaglutide 0.75 mg","deltaMin":-1.25,"sd":0.06}],"pValues":[{"comp":"OG000 vs OG001","p":"<.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":12},"locations":{"siteCount":44,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":391},"commonTop":["Constipation","Diarrhoea","Pyrexia","Covid-19","Nausea"]}}